Evidence map›Paper›PMID 40099461›Full record

ArticleImmunotherapy2025

Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT.

Markéta Šťastná-Marková, Petr Hainz, Jitka Kryštofová, Jana Macková, Kateřina Roubalová, Jan Vydra, Šárka Němečková

Abstract read
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Markéta Šťastná-MarkováTransplantation and Intensive Care Unit, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Petr HainzDepartment of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Jitka KryštofováDepartment of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Jana MackováDepartment of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Kateřina RoubalováDepartment of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Jan VydraTransplantation and Intensive Care Unit, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Šárka NěmečkováDepartment of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.ORCID 0000-0001-6001-4007

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed to examine changes in the repertoire of functional T-cells specific for six leukemia-associated antigens (LAA), including WT1, PRAME, MUC1, CCNA1, NPM1, and NPM1c, during immune reconstitution following allogeneic transplantation of hematopoietic stem cells (HSCT) in patients with acute myeloid leukemia. PATIENTS &

methodsLAA-specific T cell response was measured by ELISPOT- IFNγ and intracellular cytokine staining in 47 patients before starting conditioning therapy (baseline) and 7 months after HSCT.

resultsThe positive cumulative LAA-specific T cell response before HSCT was associated with a decreased risk of relapse after HSCT. The prevalent genetic aberration - an internal tandem duplication of Fms 3 - related receptor tyrosine kinase, which has been previously implicated in immune escape mechanisms, is presented here for the first time as a factor associated with the absence of an adaptive T cell response against multiple LAAs. T-cell specific responses against wild-type and mutated NPM1 antigens were less frequent in the study cohort and did not correlate with mutations in the NPM1 gene.

conclusionsOur results showed that the T-cell response to LAA can be reconstituted after HSCT. Measurement of functional pre-transplant T-cell responses against multiple LAAs could help to find patients with an increased risk of relapse.

Indexed as

fms-Like Tyrosine Kinase 3Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteT-LymphocytesAdolescentAdultAgedAntigens, NeoplasmFemaleHumansMaleMiddle AgedMutationNuclear ProteinsNucleophosminRecurrenceAntigens, NeoplasmFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosminacute myeloid leukemiaELISPOT-interferon gammaFlt3-ITDhematopoietic stem cell transplantationLeukemia associated antigenrelapseT cell response

Identifiers

PMID40099461
PMCPMC11951724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.